NCT01235598 - Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

September 30, 2012

Study Completion Date

May 31, 2013

Conditions

Rheumatoid Arthritis

Interventions

OTHER

Placebo

Placebo provided for the first subcutaneous injection in single-use vials at Week 0 (2 vials required), then Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4 and 6, followed by Certolizumab Pegol (CZP) 200 mg every 2 weeks from Week 8 to Week 40

BIOLOGICAL

Certolizumab Pegol (CZP) 200 mg

Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40

BIOLOGICAL

Certolizumab Pegol (CZP) 400 mg

Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40

Trial Locations (10)

Unknown

003, Frederiksberg

002, Hellerup

001, Hvidovre

016, Slagelse

012, Nijmegen

010, Utrecht

018, Warsaw

019, Warsaw

008, Gothenburg

004, Malmo